Furthermore, Nintedanib, an approved antifibrotic treatment for IPF, is a small molecule inhibitor against receptor tyrosine kinases such as PDGFR (52), which inhibits fibroblast proliferation and differentiation and ECM production in vitro. This evidence concerns the gene PDGFRB and idiopathic pulmonary fibrosis.